Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC6 | Q9UBN7 | 7/20 | 0.49 |
| ▸ | HDAC1 | Q13547 | 5/20 | 0.49 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.49 |
| ▸ | NOD1 | Q9Y239 | 10/20 | 0.45 |
| ▸ | TNF | P01375 | 9/20 | 0.45 |
| ▸ | NOD2 | Q9HC29 | 9/20 | 0.45 |
| ▸ | MEN1 | O00255 | 4/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | PLAU | P00749 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 3/20 | 0.44 |
| ▸ | NPC1 | O15118 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9950511 | 0.91 | ACACB (0.52) | NOD1TNFNOD2MEN1KMT2A | |
| SCHEMBL9960462 | 0.88 | SMN1; SMN2 (0.50) | HDAC6HDAC1HDAC8NOD1TNF | |
| SCHEMBL10104762 | 0.84 | NOD1 (0.50) | HDAC6HDAC1NOD1TNFNOD2 | |
| SCHEMBL9949384 | 0.82 | NAMPT (0.52) | HDAC6HDAC1HDAC8 | |
| SCHEMBL10104792 | 0.82 | ACACB (0.47) | NOD1TNFNOD2MEN1KMT2A | |
| SCHEMBL9949404 | 0.81 | HDAC6 (0.58) | HDAC6HDAC1HDAC8LMNA | |
| SCHEMBL12896044 | 0.74 | SMN1; SMN2 (0.62) | HDAC6HDAC1HDAC8NOD1MEN1 | |
| SCHEMBL12895811 | 0.74 | HDAC1 (0.76) | HDAC6HDAC1HDAC8NOD1TNF | |
| SCHEMBL354456 | 0.74 | HDAC8 (0.46) | HDAC6HDAC1HDAC8 | |
| SCHEMBL345519 | 0.73 | NPC1 (0.58) | NOD1NOD2MEN1KMT2ARAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8778931-B2 | Substituted hydroxamic acids and uses thereof | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2014-07-15 | — | — | US | claimed |
| US-8778931-B2 | Substituted hydroxamic acids and uses thereof | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2014-07-15 | — | — | US | disclosed |
| US-20120165316-A1 | SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2012-06-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120165316-A1 | SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF | HDAC6, HDAC5, HDAC1 | HDAC6 1/4885HDAC1 3/4885HDAC8 10/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.